Fibromyalgia predicts increased odds of pain-related addiction exacerbation among individuals with pain and opioid use disorder

Abstract

Fibromyalgia and opioid use disorder (OUD) are highly impactful chronic illnesses with substantially overlapping psychosocial, biological, and clinical features. Little previous research has examined interactions between fibromyalgia and OUD. Limiting such research has been the previous requirement of a clinical examination to diagnose fibromyalgia. The 2011 American College of Rheumatology Fibromyalgia Survey (ACR-FMS) is a validated self-report instrument with high sensitivity and specificity for fibromyalgia intended to enable fibromyalgia research in settings where a clinical examination is impractical. The present observational study uses the ACR-FMS to determine whether fibromyalgia affects odds of acknowledging pain-related OUD exacerbations among a sample of participants with pain and OUD. Participants with pain and OUD (n = 125) were recruited from an academic substance use treatment facility. The ACR-FMS, along with an original scale measuring pain-related OUD exacerbation—the Pain-related OUD Exacerbation Scale—was administered through an electronic survey. The factor structure, internal consistency, and construct validity of Pain-related OUD Exacerbation Scale were tested. In addition, descriptive analyses, multiple hierarchical linear regression, ordinal logistic regression, and multinomial logistic regression analyses were performed. Although all participants had pain, those with fibromyalgia demonstrated significantly greater odds of acknowledging pain-related OUD exacerbations. Pain-related OUD Exacerbation Scale was found to have a single-factor solution, strong internal consistency, and construct validity. This study provides first evidence of fibromyalgia as a risk factor for pain-related exacerbation of OUD and introduces a new scale with promising psychometric properties to measure pain-related OUD exacerbation.

Exploring the Relationship between Diamine Oxidase and Psychotropic Medications in Fibromyalgia Treatment, Finding No Reduction in Diamine Oxidase Levels and Activity except with Citalopram

“…A meticulous monitoring of their response to these treatments over time is essential. The positive impacts of DAO supplementation offer a promising avenue to mitigate the overuse of medications in fibromyalgia patients, thereby averting the risk of developing tolerance, dependence, and addiction [64].…”

Fibromyalgia: one year in review 2024

“…• FM is associated with an increased hazard ratio of mortality compared to the general population, especially due to accidents, infections, and suicide, while cancer-related mortality is reduced (7). • FM is associated with an increased risk of opioid use disorder (8). • Post-COVID-19 syndrome has a significant overlap with FM symptoms and exacerbates painful symptoms when coexisting with FM (9).…”